Cancer Family
Malignant Nervous System Neoplasm
CI-CAN-00000246Explore in graph →
953 active trials7 approved drugs131 evidence items
- NCIt
- C4788
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000246Explore in graph →
Clinical trials
3,457 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (495)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01903330 | ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme | unknown | Phase 2 | 84 | Epitopoietic Research CorporationINDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06353360 | TTField in Combination With Temozolomide and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma. | unknown | Phase 2 | 30 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05638451 | Sintilimab in Combination With Bevacizumab and Temozolomide in Recurrent Glioblastoma (GBM) Patients | unknown | Phase 2 | 30 | Zhujiang HospitalOTHER | 1 | Jun 5, 2024 | clinicaltrials |
| NCT04755920 | SGM-101 in Colorectal Brain Metastases.(SGM-CBM) | unknown | Phase 2 | 10 | Leiden University Medical CenterOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT00110110 | Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma | unknown | Phase 2 | 71 | The Hospital for Sick ChildrenOTHER | 4 | Apr 17, 2024 | clinicaltrials |
| NCT04600817 | A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) | unknown | Phase 2 | 160 | TJ Biopharma Co., Ltd.INDUSTRY | 2 | Apr 15, 2024 | clinicaltrials |
| NCT04573192 | A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression(GLIOSTAR) | unknown | Phase 1 / Phase 2 | 142 | Philogen S.p.A.INDUSTRY | 4 | Apr 8, 2024 | clinicaltrials |
| NCT03548571 | Dendritic Cell Immunotherapy Against Cancer Stem Cells in Glioblastoma Patients Receiving Standard Therapy(DEN-STEM) | unknown | Phase 2 / Phase 3 | 60 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06279767 | Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma | unknown | Phase 1 / Phase 2 | 27 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT05163080 | SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)(SURVIVE) | unknown | Phase 2 | 247 | MimiVax, LLCINDUSTRY | 1 | Feb 26, 2024 | clinicaltrials |
| NCT04197492 | Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade Gliomas | unknown | Phase 2 | 22 | Huashan HospitalOTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT06186440 | Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma(Glioblastoma) | unknown | Phase 1 / Phase 2 | 60 | Zhongnan HospitalOTHER | 0 | Jan 2, 2024 | clinicaltrials |
| NCT05820191 | B-amyloid as a Marker for GBM Bioimaging | unknown | Phase 2 | 3 | Universidad Central del CaribeOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT03620032 | Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses(DIPG) | unknown | Phase 2 | 54 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT03951142 | Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study(ImPRESS) | unknown | Phase 2 | 165 | Kyrre Eeg EmblemOTHER | 1 | Nov 1, 2023 | clinicaltrials |
| NCT05896007 | Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT | unknown | Phase 2 | 29 | Ruijin HospitalOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT05926427 | Orelabrutinib Combined With Rituximab and Chemotherapy for Relapsed/Refractory B-Cell Lymphoma Patients With Central Nervous System Involvement | unknown | Phase 2 | 25 | Ruijin HospitalOTHER | 1 | Sep 5, 2023 | clinicaltrials |
| NCT04671459 | TTFields and Radiosurgery of Recurrent Glioblastoma +/- 18F-Fluoro-Ethyl-Thyrosine(TaRRGET) | unknown | Phase 2 | 40 | Prof. Franciszek Lukaszczyk Memorial Oncology CenterOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT05191784 | GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients | unknown | Phase 2 | 20 | Genexine, Inc.INDUSTRY | 1 | Jun 12, 2023 | clinicaltrials |
| NCT04223999 | Improving Tumor Treating Fields Treatment for Brain Cancer Patients With Skullremodeling Surgery (Neurosurgery)(OptimalTTF-2) | unknown | Phase 2 | 70 | Anders Rosendal KorshøjOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT05816746 | Decitabine and Anti-PD-1 in R/R DLBCL | unknown | Phase 2 | 20 | Chinese PLA General HospitalOTHER | 1 | May 9, 2023 | clinicaltrials |
| NCT02137759 | MRSI to Predict Response to RT/TMZ ± Belinostat in GBM | unknown | Phase 2 | 29 | Emory UniversityOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT03561259 | A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects(OPTIMUM) | unknown | Phase 2 | 60 | Jubilant DraxImage Inc.INDUSTRY | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05694416 | Etoposide Plus Cisplatin Compared With Temozolomide in Patients With Glioblastoma | unknown | Phase 2 | 60 | Zhongnan HospitalOTHER | 0 | Jan 23, 2023 | clinicaltrials |
| NCT04840069 | Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma | unknown | Phase 2 | 100 | St. Joseph's Hospital and Medical Center, PhoenixOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT04077866 | B7-H3 CAR-T for Recurrent or Refractory Glioblastoma | unknown | Phase 1 / Phase 2 | 40 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Dec 28, 2022 | clinicaltrials |
| NCT05663125 | LITT Combined With Early Use of Temozolomide for Recurrent Glioblastomas | unknown | Phase 1 / Phase 2 | 10 | Beijing Tiantan HospitalOTHER | 1 | Dec 23, 2022 | clinicaltrials |
| NCT04481815 | Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 2 | 240 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT03750071 | VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | unknown | Phase 1 / Phase 2 | 30 | Vaximm GmbHINDUSTRY | 1 | Oct 20, 2022 | clinicaltrials |
| NCT04438044 | A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL | unknown | Phase 2 | 61 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 1 | Oct 12, 2022 | clinicaltrials |
| NCT05549284 | Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL)(RMO) | unknown | Phase 2 | 36 | Affiliated Hospital to Academy of Military Medical SciencesOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05447195 | Phase 2 Study of CAN008 in Subjects With GBM | unknown | Phase 2 | 117 | CANbridge Life Sciences Ltd.INDUSTRY | 1 | Jul 12, 2022 | clinicaltrials |
| NCT05425654 | RL-MPV Followed by BBC HCT Using Autologous Stem Cells and Maintenance Therapy With Nivolumab for Newly Diagnosed PCNSL | unknown | Phase 2 | 30 | National Research Center for Hematology, RussiaNETWORK | 1 | Jun 21, 2022 | clinicaltrials |
| NCT04831658 | A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Mingzhi ZhangOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05398224 | R-MTX-zanbrutinib in Secondary CNS Lymphoma | unknown | Phase 2 | 45 | Peking UniversityOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT05390749 | Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | unknown | Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT05385185 | Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer | unknown | Phase 2 | 20 | Hebei Medical UniversityOTHER | 1 | May 23, 2022 | clinicaltrials |
| NCT05366062 | ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab | unknown | Phase 2 | 28 | Epitopoietic Research CorporationINDUSTRY | 1 | May 13, 2022 | clinicaltrials |
| NCT02623010 | Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma | unknown | Phase 2 | 30 | Rabin Medical CenterOTHER | 1 | May 10, 2022 | clinicaltrials |
| NCT00075387 | Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors | unknown | Phase 2 | 48 | OHSU Knight Cancer InstituteOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT04514393 | Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma | unknown | Phase 2 | 33 | Huiqiang HuangOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT03400917 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma | unknown | Phase 2 | 55 | Aivita Biomedical, Inc.INDUSTRY | 1 | Dec 16, 2021 | clinicaltrials |
| NCT04888611 | Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma | unknown | Phase 2 | 40 | Huashan HospitalOTHER | 1 | Nov 30, 2021 | clinicaltrials |
| NCT05131711 | Combination of Stereotactic Radiosurgery and Enhanced Immunotherapy for Recurrent Glioblastomas(inSituVac2)(CSREIG)(CSREIG) | unknown | Phase 1 / Phase 2 | 60 | Beijing Tiantan HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05125666 | Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection | unknown | Phase 2 | 30 | Cairo UniversityOTHER | 1 | Nov 18, 2021 | clinicaltrials |
| NCT00983398 | Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors | unknown | Phase 1 / Phase 2 | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT02743429 | Phase II Study of Monoclonal Antibody ch14.18/CHO Continuous Infusion in Patients With Primary Refractory or Relapsed Neuroblastoma | unknown | Phase 2 | 40 | University Medicine GreifswaldOTHER | 2 | Oct 4, 2021 | clinicaltrials |
| NCT00293475 | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | unknown | Phase 1 / Phase 2 | 81 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT05033587 | Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma. | unknown | Phase 2 | 28 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Sep 5, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Mar 5, 2025source: clinicaltrials